[Form 4] Supernus Pharmaceuticals, Inc. Insider Trading Activity
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,412 shares of the company鈥檚 common stock on 08/22/2025. The sales were made pursuant to a Rule 10b5-1 trading plan adopted March 3, 2025, and the price reported is a weighted average of $45, with individual sale prices ranging from $45.00 to $45.01. After the reported disposition, the reporting person beneficially owned 134,232 shares, held directly.
The filing is signed on behalf of the reporting person by an attorney-in-fact, Timothy C. Dec, dated 08/26/2025. The reporting person offers to provide details of the number of shares sold at each separate price within the disclosed range upon request.
Charles W. Newhall III, amministratore di Supernus Pharmaceuticals, Inc. (SUPN), ha segnalato la vendita di 1.412 azioni del capitale sociale della societ脿 in data 22/08/2025. Le vendite sono state effettuate ai sensi di un piano di negoziazione conforme alla Regola 10b5-1 adottato il 3 marzo 2025; il prezzo riportato 猫 una media ponderata di $45, con prezzi unitari compresi tra $45,00 e $45,01. Dopo la segnalata disposizione, la persona segnalante risultava beneficiaria di 134.232 azioni, detenute direttamente.
La comunicazione 猫 firmata per conto della persona segnalante da un procuratore, Timothy C. Dec, in data 26/08/2025. La persona segnalante si rende disponibile a fornire, su richiesta, i dettagli sul numero di azioni vendute a ciascun prezzo all'interno dell'intervallo dichiarato.
Charles W. Newhall III, director de Supernus Pharmaceuticals, Inc. (SUPN), inform贸 la venta de 1.412 acciones del capital social de la compa帽铆a el 22/08/2025. Las ventas se realizaron conforme a un plan de negociaci贸n seg煤n la Regla 10b5-1 adoptado el 3 de marzo de 2025; el precio informado es un promedio ponderado de $45, con precios individuales entre $45,00 y $45,01. Tras la disposici贸n informada, la persona informante pose铆a beneficiariamente 134.232 acciones, mantenidas directamente.
La presentaci贸n est谩 firmada en nombre de la persona informante por un apoderado, Timothy C. Dec, con fecha 26/08/2025. La persona informante ofrece facilitar, a solicitud, los detalles del n煤mero de acciones vendidas a cada precio dentro del rango divulgado.
Charles W. Newhall III電� Supernus Pharmaceuticals, Inc. (SUPN)鞚� 鞚挫偓搿滌劀 2025雲� 08鞗� 22鞚� 須岇偓 氤错喌欤� 1,412欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 毵り皝鞚� 2025雲� 3鞗� 3鞚� 毂勴儩霅� 攴滌箼 10b5-1鞐� 霐半ジ 瓯半灅 瓿勴殟鞐� 鞚橅暣 鞚措（鞏挫鞙茧┌, 氤搓碃霅� 臧�瓴╈潃 臧�欷戫弶攴� $45鞚搓碃 臧滊硠 毵り皝 臧�瓴╈潃 $45.00鞐愳劀 $45.01 靷澊鞛呺媹雼�. 氤搓碃霅� 觳橂秳 頉� 頃措嫻 氤搓碃鞛愲姅 歆侅爲 氤挫湢頃橂姅 鞁れ 靻岇湢 欤检嫕 134,232欤茧ゼ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.
頃措嫻 鞝滌稖靹滊姅 氤搓碃鞛愲ゼ 雽�鞁犿晿鞐� 雽�毽秾鞚� 臧�歆� 氤�順胳偓 Timothy C. Dec臧� 2025雲� 08鞗� 26鞚检棎 靹滊獏頄堨姷雼堧嫟. 氤搓碃鞛愲姅 瓿店皽霅� 氩旍渼 雮� 臧� 臧滊硠 臧�瓴╇硠搿� 毵り皝霅� 欤检嫕 靾橃棎 雽�頃� 靹鸽秬 鞝曤炒毳� 鞖旍箔 鞁� 鞝滉车頃橁矤雼り碃 氚濏様鞀惦媹雼�.
Charles W. Newhall III, administrateur de Supernus Pharmaceuticals, Inc. (SUPN), a d茅clar茅 la vente de 1 412 actions du capital social de la soci茅t茅 le 22/08/2025. Les ventes ont 茅t茅 effectu茅es conform茅ment 脿 un plan de n茅gociation en vertu de la r猫gle 10b5-1 adopt茅 le 3 mars 2025 ; le prix d茅clar茅 est une moyenne pond茅r茅e de 45 $, avec des prix individuels allant de 45,00 $ 脿 45,01 $. Apr猫s la cession d茅clar茅e, la personne d茅clarante d茅tenait 脿 titre b茅n茅ficiaire 134 232 actions, d茅tenues directement.
Le d茅p么t est sign茅 au nom de la personne d茅clarante par un mandataire, Timothy C. Dec, en date du 26/08/2025. La personne d茅clarante se propose de fournir, sur demande, les d茅tails du nombre d'actions vendues 脿 chaque prix individuel dans la fourchette divulgu茅e.
Charles W. Newhall III, ein Direktor von Supernus Pharmaceuticals, Inc. (SUPN), meldete den Verkauf von 1.412 Aktien des Stammkapitals des Unternehmens am 22.08.2025. Die Verk盲ufe erfolgten im Rahmen eines nach Rule 10b5-1 eingerichteten Handelsplans, der am 3. M盲rz 2025 angenommen wurde; der gemeldete Preis ist ein gewichteter Durchschnitt von $45, wobei die einzelnen Verkaufspreise zwischen $45,00 und $45,01 lagen. Nach der gemeldeten Verf眉gung hielt die meldende Person wirtschaftlich 134.232 Aktien, die direkt gehalten wurden.
Die Einreichung ist im Namen der meldenden Person von einem Bevollm盲chtigten, Timothy C. Dec, datiert 26.08.2025, unterzeichnet. Die meldende Person bietet an, auf Anfrage Einzelheiten zur Anzahl der zu jedem einzelnen Preis verkauften Aktien innerhalb der angegebenen Spanne bereitzustellen.
- Transaction executed under a 10b5-1 trading plan, indicating it was pre-authorized
- Weighted average sale price disclosed ($45) and range ($45.00鈥�$45.01) with offer to provide per-price details on request
- Post-transaction beneficial ownership disclosed (134,232 shares), providing transparency
- Disposition of 1,412 shares reduced the reporting person鈥檚 direct holdings
- No information on total outstanding shares or percentage ownership is provided in this filing, limiting context
Insights
TL;DR: Routine insider sale under a 10b5-1 plan; modest reduction in direct holdings does not by itself indicate a material change to ownership.
The report shows a small block disposal of 1,412 shares at an average price of $45 under a pre-established 10b5-1 plan adopted March 3, 2025. The filing discloses the post-transaction direct beneficial ownership of 134,232 shares. For investors, this is a transparent, rule-compliant insider sale; the size of the sale relative to total holdings reported here appears limited. No derivative transactions or additional material changes to ownership are reported.
TL;DR: Compliance-focused disclosure: the sale was executed under a documented 10b5-1 plan and properly reported on Form 4.
The filing explicitly states the transaction was made pursuant to a 10b5-1 trading plan and provides the weighted average price and the disclosed price range. Signature by an attorney-in-fact is included. From a governance perspective, the form meets disclosure requirements and offers additional transparency by offering to provide per-price sale breakdowns on request. No stock option exercises, grants, or other governance actions are included in this filing.
Charles W. Newhall III, amministratore di Supernus Pharmaceuticals, Inc. (SUPN), ha segnalato la vendita di 1.412 azioni del capitale sociale della societ脿 in data 22/08/2025. Le vendite sono state effettuate ai sensi di un piano di negoziazione conforme alla Regola 10b5-1 adottato il 3 marzo 2025; il prezzo riportato 猫 una media ponderata di $45, con prezzi unitari compresi tra $45,00 e $45,01. Dopo la segnalata disposizione, la persona segnalante risultava beneficiaria di 134.232 azioni, detenute direttamente.
La comunicazione 猫 firmata per conto della persona segnalante da un procuratore, Timothy C. Dec, in data 26/08/2025. La persona segnalante si rende disponibile a fornire, su richiesta, i dettagli sul numero di azioni vendute a ciascun prezzo all'interno dell'intervallo dichiarato.
Charles W. Newhall III, director de Supernus Pharmaceuticals, Inc. (SUPN), inform贸 la venta de 1.412 acciones del capital social de la compa帽铆a el 22/08/2025. Las ventas se realizaron conforme a un plan de negociaci贸n seg煤n la Regla 10b5-1 adoptado el 3 de marzo de 2025; el precio informado es un promedio ponderado de $45, con precios individuales entre $45,00 y $45,01. Tras la disposici贸n informada, la persona informante pose铆a beneficiariamente 134.232 acciones, mantenidas directamente.
La presentaci贸n est谩 firmada en nombre de la persona informante por un apoderado, Timothy C. Dec, con fecha 26/08/2025. La persona informante ofrece facilitar, a solicitud, los detalles del n煤mero de acciones vendidas a cada precio dentro del rango divulgado.
Charles W. Newhall III電� Supernus Pharmaceuticals, Inc. (SUPN)鞚� 鞚挫偓搿滌劀 2025雲� 08鞗� 22鞚� 須岇偓 氤错喌欤� 1,412欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 毵り皝鞚� 2025雲� 3鞗� 3鞚� 毂勴儩霅� 攴滌箼 10b5-1鞐� 霐半ジ 瓯半灅 瓿勴殟鞐� 鞚橅暣 鞚措（鞏挫鞙茧┌, 氤搓碃霅� 臧�瓴╈潃 臧�欷戫弶攴� $45鞚搓碃 臧滊硠 毵り皝 臧�瓴╈潃 $45.00鞐愳劀 $45.01 靷澊鞛呺媹雼�. 氤搓碃霅� 觳橂秳 頉� 頃措嫻 氤搓碃鞛愲姅 歆侅爲 氤挫湢頃橂姅 鞁れ 靻岇湢 欤检嫕 134,232欤茧ゼ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.
頃措嫻 鞝滌稖靹滊姅 氤搓碃鞛愲ゼ 雽�鞁犿晿鞐� 雽�毽秾鞚� 臧�歆� 氤�順胳偓 Timothy C. Dec臧� 2025雲� 08鞗� 26鞚检棎 靹滊獏頄堨姷雼堧嫟. 氤搓碃鞛愲姅 瓿店皽霅� 氩旍渼 雮� 臧� 臧滊硠 臧�瓴╇硠搿� 毵り皝霅� 欤检嫕 靾橃棎 雽�頃� 靹鸽秬 鞝曤炒毳� 鞖旍箔 鞁� 鞝滉车頃橁矤雼り碃 氚濏様鞀惦媹雼�.
Charles W. Newhall III, administrateur de Supernus Pharmaceuticals, Inc. (SUPN), a d茅clar茅 la vente de 1 412 actions du capital social de la soci茅t茅 le 22/08/2025. Les ventes ont 茅t茅 effectu茅es conform茅ment 脿 un plan de n茅gociation en vertu de la r猫gle 10b5-1 adopt茅 le 3 mars 2025 ; le prix d茅clar茅 est une moyenne pond茅r茅e de 45 $, avec des prix individuels allant de 45,00 $ 脿 45,01 $. Apr猫s la cession d茅clar茅e, la personne d茅clarante d茅tenait 脿 titre b茅n茅ficiaire 134 232 actions, d茅tenues directement.
Le d茅p么t est sign茅 au nom de la personne d茅clarante par un mandataire, Timothy C. Dec, en date du 26/08/2025. La personne d茅clarante se propose de fournir, sur demande, les d茅tails du nombre d'actions vendues 脿 chaque prix individuel dans la fourchette divulgu茅e.
Charles W. Newhall III, ein Direktor von Supernus Pharmaceuticals, Inc. (SUPN), meldete den Verkauf von 1.412 Aktien des Stammkapitals des Unternehmens am 22.08.2025. Die Verk盲ufe erfolgten im Rahmen eines nach Rule 10b5-1 eingerichteten Handelsplans, der am 3. M盲rz 2025 angenommen wurde; der gemeldete Preis ist ein gewichteter Durchschnitt von $45, wobei die einzelnen Verkaufspreise zwischen $45,00 und $45,01 lagen. Nach der gemeldeten Verf眉gung hielt die meldende Person wirtschaftlich 134.232 Aktien, die direkt gehalten wurden.
Die Einreichung ist im Namen der meldenden Person von einem Bevollm盲chtigten, Timothy C. Dec, datiert 26.08.2025, unterzeichnet. Die meldende Person bietet an, auf Anfrage Einzelheiten zur Anzahl der zu jedem einzelnen Preis verkauften Aktien innerhalb der angegebenen Spanne bereitzustellen.
FAQ
What did Charles W. Newhall III report on Form 4 for SUPN?
Was the sale by the SUPN director part of a 10b5-1 plan?
What price was reported for the shares sold in the SUPN Form 4?
How many SUPN shares does the reporting person own after the sale?
Who signed the Form 4 for the SUPN reporting person?
